Malaria Vaccines for the World

8-10 May 2019, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 8th May 2019

08.30 onwards
Registration

SESSION 1:
OPENING PLENARY SESSION

Moderator: Simon Draper (University of Oxford, Oxford, UK)

09.30-10.00
‘Subunit vaccines for malaria – getting there!’
Adrian V.S. Hill (University of Oxford, Oxford, UK)

10.00-10.30
‘Developing vaccines to battle the complex parasites that cause malaria in heterogeneous populations is not for the faint of heart: The PfSPZ experience’
Stephen Hoffmann (Sanaria Inc., Maryland, USA)

10.30-11.00
Coffee Break & Posters Set-Up

SESSION 2: PfSPZ-Based Vaccines:
Phase 3 to Licensure to Deployment to Use in Elimination Campaigns to Next Generations

Moderators: Said Jongo (Ifakara Health Institute, Ifakara, Tanzania) and Marcel Tanner (Swiss TPH, Switzerland)

11.00-11.15
‘Finalizing an immunization regimen for PfSPZ Vaccine for Phase 3 clinical trials in non-immunes’
Stephen L. Hoffman (Sanaria Inc., Maryland, USA)

11.15-11.30
‘Finalizing an immunization regimen for PfSPZ Vaccine for Phase 3 clinical trials in semi-immune adults in Africa’
Said Jongo (Ifakara Health Institute and Bioko Island Malaria Elimination Program)

11.30-11.45
‘Current status of and medium-term plans for PfSPZ Vaccine’
Thomas L. Richie (Sanaria Inc., Maryland, USA)

11.45-12.00
‘Plans for use of PfSPZ Vaccine for Geographically Focused Elimination Campaigns’
Salim Abdulla (Ifakara Health Institute and Bioko Island Malaria Elimination Program)

12.00-12.15
‘Developing a PfSPZ-CVac regimen that provides high level protection against heterologous CHMI’
Agnes Mwakingwe (Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH, Bethesda, Maryland, USA)

12.15-12.30
‘Current status of early arresting genetically altered PfSPZ vaccines, PfSPZ-GA1’
Shahid Khan and Meta Roestenberg (Leiden University Medical Center, Leiden, The Netherlands)

12.30-12.45
‘Current status of early arresting genetically altered PfSPZ vaccines, PfSPZ-GAP3KO’
Ashley Vaughan (Seattle Children’s Hospital Research Foundation, Seattle, Washington, USA)

12.45-13.00
Discussion

13.00-13.45
Lunch Break & Posters

SESSION 3: PfSPZ-Based Vaccines:
Innovations and immunology to improve efficacy and reduce cost of goods

Moderators: Patrick Duffy (LMIV, NIAID, NIH) and Peter F. Billingsley (Sanaria Inc., Maryland, USA)

13.45-14.00
‘Production of fully infectious, immunogenic PfSPZ in vitro
Abraham Eappen (Sanaria Inc., Maryland, USA)

14.00-14.15
‘Hybrid strains and mixed strains of PfSPZ for increasing genetic diversity’
B. Kim Lee Sim (Sanaria Inc., Maryland, USA)

14.15-14.30
‘Development of late liver stage arresting genetically attenuated PfSPZ and parasites expressing heterologous antigens’
Shahid Khan and Chris Janse (Leiden University Medical Center, Leiden, The Netherlands)

14.30-14.45
‘Development of late liver stage arresting genetically attenuated PfSPZ and parasites expressing heterologous antigens’
Stefan Kappe (Seattle Children’s Hospital Research Foundation, Seattle, Washington, USA)

14.45-15.00
‘Improving immunogenicity with adjuvants’
Sumana Chakravarty (Sanaria Inc., Maryland, USA)

15.00-15.15
‘What have we learned and not learned from immunological studies during vaccine efficacy studies?’
Claudia Daubenberger (Swiss TPH, Switzerland)

15.15-15.30
‘Complementing protection with human monoclonal antibodies’
Stephen L. Hoffman (Sanaria Inc., Maryland, USA)

15.30-16.00
Tea Break & Posters

SESSION 4:
RECENT ADVANCES – BLOOD-STAGE VACCINES

Moderators: Evelina Angov (Walter Reed Army Institute of Research, USA) and Chetan Chitnis (Institut Pasteur, France & ICGEB, India)

16.00-16.15
‘Safety, immunogenicity and efficacy of the Plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a Phase I/IIa clinical trial’
Angela M. Minassian1, Sarah E. Silk1, Jordan R. Barrett1, Ian D. Poulton1, Celia H. Mitton1, Ruth O. Payne1, Thomas A. Rawlinson1, Megan Baker1, Raquel Lopez Ramon1, Fernando Ramos Lopez1, Nick J. Edwards1, Katherine J. Ellis1, Carolyn M. Nielsen1, Doris Quinkert1, Lea Barfod1, Kazutoyo Miura2, Ababacar Diouf2, Yrene Themistocleous1, Pedro Folegatti1, Daniel Silman1, Mehreen Datoo1, Willem A. de Jongh3, Robert Smith1, Eleanor Berrie1, Danielle Morelle4, Marc Lievens4, Amy R. Noe5, Carter L. Diggs6, Lorraine A. Soisson6, Rebecca Ashfield1, Carole A. Long2, Fay L. Nugent1, Alison M. Lawrie1 and Simon J. Draper1 (1 The Jenner Institute, University of Oxford, United Kingdom; 2 Laboratory of Malaria and Vector Research, NIAID/NIH, USA; 3 ExpreS2ion Biotechnologies, Denmark; 4 GSK, Wavre, Belgium; 5 Leidos Life Sciences, USA; 6 Malaria Vaccine Development Program, USAID, USA)

16.15-16.30
‘Superior antigen-specific T follicular helper (Tfh) cell responses to blood-stage malaria antigen RH5 are induced with a protein/AS01 vaccine platform as compared to heterologous viral vectors’
Carolyn M. Nielsen, Ane Ogbe, Isabela Pedroza-Pacheco, Susanne Doeleman, Sarah E. Silk, Jordan R. Barrett, Sean C. Elias, Ruth O. Payne, Angela M. Minassian, Simon J. Draper and Persephone Borrow (University of Oxford, Oxford, UK)

16.30-16.45
‘Status of PfEMP1 vaccine development’
Louise Turner, Morten Nielsen, Ali Salanti, Thor G. Theande and Thomas Lavstsen (University of Copenhagen, Copenhagen, Denmark)

 

MVW 2019 Delegates

Login details will be supplied after you have registered for the event.


MVW 2019 Sponsors

  • MW Journal
  • NatureGeneTherapy.com
  • DNAvaccine.com
  • Malaria No More
  • Malaria World
  • Mymetics
  • Sanaria
  • EVI
  • Aldevron
  • MVI PATH
  • Inovio Pharmaceuticals
  • VisMederi

MVW 2019 Downloads

MVW 2019 Leaflet

MVW 2019 Mailing List

Name
E-mail Address
What is 3+2-1?